PDF
File
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, September 29, 2020 - ExpreS2ion Biotech Holding AB ("ExpreS2ion") hereby announces the launch of a significantly upgraded company website. The new website has a stronger focus on ExpreS2ion's novel technology platforms and the company's pipeline project development. It also introduces a separate investor site for improved communication with shareholders, potential investors and other parties of interest.
Additional enhancements include easier access to ExpreS[2]ion's online store, where customers are offered a broad range of viral antigens, transfection reagents and an ExpreS[2] kit for starting up new development projects.
ExpreS[2]ion's CEO Bent Frandsen comments:
"With promising vaccines for Covid-19 and breast cancer in development using our two novel technology platforms, while also providing development services and antigens to partners and customers, ExpreS[2]ion is now an established vaccine development company. I hope that our new website is able to convey this and strike a good balance between our business areas, so that we can continue to utilise it as an important tool in our communication with shareholders, partners and customers."
The new website is available now at www.expres2ionbio.com
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 11 32 30 732
Email: ca@skmg.se